TLR4 and inflammatory bowel disease: In vitro, PSP-1b directly interacted with TLR4, inhibited the MAPK/NF-κB signaling pathway, and attenuated LPS- and NET-induced macrophage polarization and inflammation.<h4>Conclusions</h4>PSP-1b as a promising candidate for functional foods or therapeutic agents targeting inflammatory bowel disease.